PNV Discussion 2022

[Moosey]

I thought others might like to know what Polynovo does?

PolyNovo | Healing. Redefined.

At PolyNovo, we're driven by improving the outcomes of patients through development & provision of revolutionary synthetic skin substitutes.

polynovo.com

• Company
• Products
• BTM for HCPs
• News and Events
• Investor
• Contact
• Region

About Us​

Improving Outcomes.
Changing Lives.​

We recognize that many of the lives of those who need our products have been touched by tragedy and are changed forever.​

At PolyNovo we are driven by improving the outcomes of patients through development and provision of the best surgical solutions possible.
PolyNovo develops innovative medical devices utilizing the patented bioabsorbable polymer technology Novosorb®.
NovoSorb is a family of proprietary medical grade polymers that can be expressed in a variety of physical formats. NovoSorb polymers have advantageous properties such as biocompatibility and design flexibility. These properties underpin novel medical devices designed to support tissue repair, before they biodegrade in situ into biocompatible by-products via established pathways.
NovoSorb BTM (Biodegradable Temporizing Matrix) is the first product commercialized by PolyNovo. In 2015, following the FDA 510(K) clearance of BTM, PolyNovo was awarded an $11 million contract and a further $25 million in funding from the US-based Biomedical Advanced Research and Development Authority (BARDA) to complete a trial with BTM for full thickness burns.
We have expanded our manufacturing facility and headquarters in Melbourne, Australia, establishing high quality processes, enabling product innovation and preparing for growth.

NovoSorb BTM Milestones​

2015​

United States 510(K) clearance and commercialisation

2016​

South African distribution agreement

2018​

Distribution partnerships in Saudi Arabia, Israel and India

2018​

Australian ARTG listing and commercialisation.

2019​

Registered in Singapore and Malaysia

2019​

Distribution partnership for Germany, Austria and Switzerland

2019​

Awarded European CE mark

2020​

European commercialisation.

Corporate Governance​

• ISO 13485 Certificate
• CE Certificate QA System
• CE Certificate BTM
• Corporate Governance Statement
• PolyNovo Board Charter
• Market Disclosure Protocol
• PolyNovo Share Trading Policy
• Communications Policy
• Audit and Risk Committee Charter
• PolyNovo Gender Diversity Policy
• Remuneration and Nomination Committee
• PolyNovo Risk Management Policy
• Commercial Code of Conduct
• Whistleblower Policy
• Modern Slavery Statement
• Health & Safety Policy
• Environment Policy

• 
  © Copyright PolyNovo Limited 2021.
  PolyNovo and NovoSorb are registered
  trademarks of PolyNovo Biomaterials Pty Ltd.
  Privacy Policy and Disclaimer

• V2.0 November 2021

 

[Lattelarry]

I like the sound of this new technology, https://scitechdaily.com/human-spin...y-enable-people-with-paralysis-to-walk-again/

I wonder if they will need an inert scaffold to place the stem cells in, what a wonderful thing that would be to see people who have damaged spines walk again, hopefully the future is looking brighter for them.

Moosey check this out - a Swiss company working on spinal but with a very different method: https://12ft.io/proxy?q=https://www...-people-to-walk-swim-and-cycle-again/21807596

 

[Moosey]

Moosey check this out - a Swiss company working on spinal but with a very different method: https://12ft.io/proxy?q=https://www.economist.com/science-and-technology/spinal-implants-allow-paralysed-people-to-walk-swim-and-cycle-again/21807596

Sound like a great idea, LL but I do think a method that uses stem cells to achieve the same result would actually be better as it is actually repairing the spinal cord, not manipulating it with an electrical device which would need maintanence over time, that the way I see it anyway?

As yo say your LL not sure if a matrix would be required or not? perhaps a very thin sheet of BTM seeded with these modified stem cells could be wrapped around the spinal cord where it has been damaged and would allow the growth of new cells to repair the cord again back to full function?

Just a thought here!

 

[Moosey]

I found this on the other site, it was posted by Bedger (thanks)-: " If PNV investors en masse told their brokers not to lend their stock for shorting, it would create a short squeeze as custodians would not be able to borrow stock to cover the risk and force their clients to buy back short positions."

I have notified my brokers that I in no way want my shares lent for shorting purposes, maybe others should do the same, if they don't want their shares lent for shorting purposes!

I was told by both Comsec and Westpac that they do not do this, but some brokers do!

 

[Space Cadet]

Moosey,

I would prefer no shorting but I think it should be legislated that they have to ask you if they can lend your shares. Don't know how it could even be legal to lend out shares you own. Of course you don't own them in funds etc.

SC

 

[Lattelarry]

Moosey,

I would prefer no shorting but I think it should be legislated that they have to ask you if they can lend your shares. Don't know how it could even be legal to lend out shares you own. Of course you don't own them in funds etc.

SC

Im pretty sure IB works like this where you have to actively say you want your shares lent out.

 

[Moosey]

An old article but still valid.

Is Biodegradable Temporising Matrix a new-age hero of dermal scaffolds and wound closure? The experience in a quaternary paediatric hospital. – 2024 ANZBA Annual Scientific Meeting

www.anzbaasm.com

Is Biodegradable Temporising Matrix a new-age hero of dermal scaffolds and wound closure? The experience in a quaternary paediatric hospital.​

Dr Alicia Miers1,2,3, Dr Aoife Rice1,2,3, Ms Kristen Storey1,2,3, Dr Yun Phua1, Professor Roy Kimble1,2,3,4
1Queensland Children’s Hospital, South Brisbane, Australia, 2University of Queensland, St Lucia, Australia, 3Pegg Leditschke Children’s Burns Centre, Queensland Children’s Hospital, Brisbane, Australia, 4Queensland University of Technology, Brisbane, Australia

Abstract:​

Novosorb™ Biodegradable Temporising Matrix (BTM) provides a fully synthetic dermal scaffold for tissue repair, and contributes to stable, durable and flexible wound closure (Cheshire et al. 2016).
Retrospective chart review revealed nine children where BTM was used between October 2018 and May 2019 at Queensland Children’s Hospital. A majority of patients were managed through the Pegg Leditschke Children’s Burns Centre.
The injuries and conditions included in this series all resulted in full thickness skin defects prompting operative intervention for surgical debridement, dressings, application of BTM and 7 out of 9 patients required skin grafting. In a total of 9 patients, BTM was used on 27 sites. Conditions requiring wound management where BTM was used included electrical injuries resulting in full thickness burns, scar contracture releases, lower limb ulceration in the context of ataxia telangiectasia, excision of an epidermal naevus on the posterior neck, and skin necrosis arterial thrombus as well as necrosis complicating sclerotherapy of a venous malformation of the scalp.
At the time of submission, BTM had incorporated well into the sites of all patients within three to five weeks. In small areas, BTM did not require grafting. Two patients had an unexpected return to theatre for bleeding and there was one graft failure in the context of pseudomonas infection requiring re-grafting.
Reports of BTM use in the Australian context are limited and this case series aims to reflect on the experience in our hospital and highlight the versatility and durability of BTM in the management of complex wounds.
Reference List
Cheshire, PA, Herson, MR, Cleland, H & Akbarzadeh, S 2016, Artificial dermal templates: A comparative study of NovoSorb™ Biodegradable Temporising Matrix (BTM) and Integra ® Dermal Regeneration Template (DRT), 03054179

---

Biography:​

Dr Alicia Miers is a Registrar with the Paediatric Surgery, Urology, Burns and Trauma Unit at Queensland Children’s Hospital.

 

[Moosey]

An old article but still valid.

Is Biodegradable Temporising Matrix a new-age hero of dermal scaffolds and wound closure? The experience in a quaternary paediatric hospital. – 2024 ANZBA Annual Scientific Meeting

www.anzbaasm.com

Is Biodegradable Temporising Matrix a new-age hero of dermal scaffolds and wound closure? The experience in a quaternary paediatric hospital.​

Dr Alicia Miers1,2,3, Dr Aoife Rice1,2,3, Ms Kristen Storey1,2,3, Dr Yun Phua1, Professor Roy Kimble1,2,3,4
1Queensland Children’s Hospital, South Brisbane, Australia, 2University of Queensland, St Lucia, Australia, 3Pegg Leditschke Children’s Burns Centre, Queensland Children’s Hospital, Brisbane, Australia, 4Queensland University of Technology, Brisbane, Australia

Abstract:​

Novosorb™ Biodegradable Temporising Matrix (BTM) provides a fully synthetic dermal scaffold for tissue repair, and contributes to stable, durable and flexible wound closure (Cheshire et al. 2016).
Retrospective chart review revealed nine children where BTM was used between October 2018 and May 2019 at Queensland Children’s Hospital. A majority of patients were managed through the Pegg Leditschke Children’s Burns Centre.
The injuries and conditions included in this series all resulted in full thickness skin defects prompting operative intervention for surgical debridement, dressings, application of BTM and 7 out of 9 patients required skin grafting. In a total of 9 patients, BTM was used on 27 sites. Conditions requiring wound management where BTM was used included electrical injuries resulting in full thickness burns, scar contracture releases, lower limb ulceration in the context of ataxia telangiectasia, excision of an epidermal naevus on the posterior neck, and skin necrosis arterial thrombus as well as necrosis complicating sclerotherapy of a venous malformation of the scalp.
At the time of submission, BTM had incorporated well into the sites of all patients within three to five weeks. In small areas, BTM did not require grafting. Two patients had an unexpected return to theatre for bleeding and there was one graft failure in the context of pseudomonas infection requiring re-grafting.
Reports of BTM use in the Australian context are limited and this case series aims to reflect on the experience in our hospital and highlight the versatility and durability of BTM in the management of complex wounds.
Reference List
Cheshire, PA, Herson, MR, Cleland, H & Akbarzadeh, S 2016, Artificial dermal templates: A comparative study of NovoSorb™ Biodegradable Temporising Matrix (BTM) and Integra ® Dermal Regeneration Template (DRT), 03054179

---

Biography:​

Dr Alicia Miers is a Registrar with the Paediatric Surgery, Urology, Burns and Trauma Unit at Queensland Children’s Hospital.

Just wondering if a small thin BTM wrapped around the spinal cord seeded with modified stem cells improve this?

Regenerative Medicine Breakthrough: “Dancing Molecules” Successfully Repair Severe Spinal Cord Injuries

After single injection, paralyzed animals regained ability to walk within four weeks. Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal cord injuries. In a new study, researc

scitechdaily.com

Regenerative Medicine Breakthrough: “Dancing Molecules” Successfully Repair Severe Spinal Cord Injuries​

TOPICS:Northwestern UniversityPopularRegenerative MedicineSpinal Cord

By Northwestern University November 12, 2021


Longitudinal spinal cord section treated with the most bioactive therapeutic scaffold. Regenerated axons (red) regrew within the lesion. Credit: Samuel I. Stupp Laboratory/Northwestern University
After single injection, paralyzed animals regained ability to walk within four weeks.
Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal cord injuries.
In a new study, researchers administered a single injection to tissues surrounding the spinal cords of paralyzed mice. Just four weeks later, the animals regained the ability to walk.

The research will be published in the November 12, 2021, issue of the journal Science.

Longitudinal spinal cord section treated with the most bioactive therapeutic scaffold, captured 12 weeks after injury. Blood vessels (red) regenerated within the lesion. Laminin is stained in green and cells are stained in blue. Credit: Samuel I. Stupp Laboratory/Northwestern University
By sending bioactive signals to trigger cells to repair and regenerate, the breakthrough therapy dramatically improved severely injured spinal cords in five key ways: (1) The severed extensions of neurons, called axons, regenerated; (2) scar tissue, which can create a physical barrier to regeneration and repair, significantly diminished; (3) myelin, the insulating layer of axons that is important in transmitting electrical signals efficiently, reformed around cells; (4) functional blood vessels formed to deliver nutrients to cells at the injury site; and (5) more motor neurons survived.
After the therapy performs its function, the materials biodegrade into nutrients for the cells within 12 weeks and then completely disappear from the body without noticeable side effects. This is the first study in which researchers controlled the collective motion of molecules through changes in chemical structure to increase a therapeutic’s efficacy.

A simple animation shows how a single injection restores connections in the nervous system below the site of a severe spinal cord injury. Credit: Samuel I. Stupp Laboratory/Mark Seniw/Northwestern University
“Our research aims to find a therapy that can prevent individuals from becoming paralyzed after major trauma or disease,” said Northwestern’s Samuel I. Stupp, who led the study. “For decades, this has remained a major challenge for scientists because our body’s central nervous system, which includes the brain and spinal cord, does not have any significant capacity to repair itself after injury or after the onset of a degenerative disease. We are going straight to the FDA to start the process of getting this new therapy approved for use in human patients, who currently have very few treatment options.”
Stupp is Board of Trustees Professor of Materials Science and Engineering, Chemistry, Medicine and Biomedical Engineering at Northwestern, where he is founding director of the Simpson Querrey Institute for BioNanotechnology (SQI) and its affiliated research center, the Center for Regenerative Nanomedicine. He has appointments in the McCormick School of Engineering, Weinberg College of Arts and Sciences, and Feinberg School of Medicine.

A paralyzed mouse (left) drags its hind legs, compared to a paralyzed mouse that has regained its ability to move its legs after receiving Northwestern’s injectable therapy. Credit: Samuel I. Stupp Laboratory/Northwestern University

Life expectancy has not improved since the 1980s​

According to the National Spinal Cord Injury Statistical Center, nearly 300,000 people are currently living with a spinal cord injury in the United States. Life for these patients can be extraordinarily difficult. Less than 3% of people with complete injury ever recover basic physical functions. And approximately 30% are re-hospitalized at least once during any given year after the initial injury, costing millions of dollars in average lifetime health care costs per patient. Life expectancy for people with spinal cord injuries is significantly lower than people without spinal cord injuries and has not improved since the 1980s.

“I wanted to make a difference on the outcomes of spinal cord injury and to tackle this problem, given the tremendous impact it could have on the lives of patients.”
— Samuel I. Stupp, materials scientist

“Currently, there are no therapeutics that trigger spinal cord regeneration,” said Stupp, an expert in regenerative medicine. “I wanted to make a difference on the outcomes of spinal cord injury and to tackle this problem, given the tremendous impact it could have on the lives of patients. Also, new science to address spinal cord injury could have impact on strategies for neurodegenerative diseases and stroke.”

‘Dancing molecules’ hit moving targets​

The secret behind Stupp’s new breakthrough therapeutic is tuning the motion of molecules, so they can find and properly engage constantly moving cellular receptors. Injected as a liquid, the therapy immediately gels into a complex network of nanofibers that mimic the extracellular matrix of the spinal cord. By matching the matrix’s structure, mimicking the motion of biological molecules and incorporating signals for receptors, the synthetic materials are able to communicate with cells.
“Receptors in neurons and other cells constantly move around,” Stupp said. “The key innovation in our research, which has never been done before, is to control the collective motion of more than 100,000 molecules within our nanofibers. By making the molecules move, ‘dance’ or even leap temporarily out of these structures, known as supramolecular polymers, they are able to connect more effectively with receptors.”

Nanofibers containing molecules that bear two different bioactive signals (green and orange) more effectively engage cell receptors (yellow and blue) as a result of the molecules’ fast motion. Credit: Samuel I. Stupp Laboratory/Mark Seniw/Northwestern University
Stupp and his team found that fine-tuning the molecules’ motion within the nanofiber network to make them more agile resulted in greater therapeutic efficacy in paralyzed mice. They also confirmed that formulations of their therapy with enhanced molecular motion performed better during in vitro tests with human cells, indicating increased bioactivity and cellular signaling.
“Given that cells themselves and their receptors are in constant motion, you can imagine that molecules moving more rapidly would encounter these receptors more often,” Stupp said. “If the molecules are sluggish and not as ‘social,’ they may never come into contact with the cells.”

One injection, two signals​

Once connected to the receptors, the moving molecules trigger two cascading signals, both of which are critical to spinal cord repair. One signal prompts the long tails of neurons in the spinal cord, called axons, to regenerate. Similar to electrical cables, axons send signals between the brain and the rest of the body. Severing or damaging axons can result in the loss of feeling in the body or even paralysis. Repairing axons, on the other hand, increases communication between the body and brain.
The second signal helps neurons survive after injury because it causes other cell types to proliferate, promoting the regrowth of lost blood vessels that feed neurons and critical cells for tissue repair. The therapy also induces myelin to rebuild around axons and reduces glial scarring, which acts as a physical barrier that prevents the spinal cord from healing.

A new injectable therapy forms nanofibers with two different bioactive signals (green and orange) that communicate with cells to initiate repair of the injured spinal cord. Credit: Illustration by Mark Seniw
“The signals used in the study mimic the natural proteins that are needed to induce the desired biological responses. However, proteins have extremely short half-lives and are expensive to produce,” said Zaida Álvarez, the study’s first author. “Our synthetic signals are short, modified peptides that — when bonded together by the thousands — will survive for weeks to deliver bioactivity. The end result is a therapy that is less expensive to produce and lasts much longer.”
A former research assistant professor in Stupp’s laboratory, Álvarez is now a visiting scholar at SQI and a researcher at the Institute for Bioengineering of Catalona in Spain.

Universal application​

While the new therapy could be used to prevent paralysis after major trauma (automobile accidents, falls, sports accidents and gunshot wounds) as well as from diseases, Stupp believes the underlying discovery — that “supramolecular motion” is a key factor in bioactivity — can be applied to other therapies and targets.
“The central nervous system tissues we have successfully regenerated in the injured spinal cord are similar to those in the brain affected by stroke and neurodegenerative diseases, such as ALS, Parkinson’s disease and Alzheimer’s disease,” Stupp said. “Beyond that, our fundamental discovery about controlling the motion of molecular assemblies to enhance cell signaling could be applied universally across biomedical targets.”
Reference: “Bioactive scaffolds with enhanced supramolecular motion promote recovery from spinal cord injury” by Z. Álvarez, A. N. Kolberg-Edelbrock, I. R. Sasselli, J. A. Ortega, R. Qiu, Z. Syrgiannis, P. A. Mirau, F. Chen, S. M. Chin, S. Weigand, E. Kiskinis and S. I. Stupp, 11 November 2021, Science.
DOI: 10.1126/science.abh3602
Other Northwestern study authors include Evangelos Kiskinis, assistant professor of neurology and neuroscience in Feinberg; research technician Feng Chen; postdoctoral researchers Ivan Sasselli, Alberto Ortega and Zois Syrgiannis; and graduate students Alexandra Kolberg-Edelbrock, Ruomeng Qiu and Stacey Chin. Peter Mirau of the Air Force Research Laboratories and Steven Weigand of Argonne National Laboratory also are co-authors.
The study, “Bioactive scaffolds with enhanced supramolecular motion promote recovery from spinal cord injury,” was supported by the Louis A. Simpson and Kimberly K. Querrey Center for Regenerative Nanomedicine at the Simpson Querrey Institute for BioNanotechnology, the Air Force Research Laboratory (award number FA8650-15-2-5518), National Institute of Neurological Disorders and Stroke and the National Institute on Aging (award numbers R01NS104219, R21NS107761 and R21NS107761-01A1), the Les Turner ALS Foundation, the New York Stem Cell Foundation, the Paralyzed Veterans of America Research Foundation (award number PVA17RF0008), the National Science Foundation and the French Muscular Dystrophy Association.

 

[Moosey]

Looks like others have tried using biomaterial matrices in the spinal cord namely
NeuroRegen Scaffold™ and RMx Biomatrix™ both of which I believe both are collagen based?
They say they use it for Cartlige repair also see here-: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250655/

Abstract​

Background:​

Cartilage tissue engineering (CTE) aims to obtain a structure mimicking native cartilage tissue through the combination of relevant cells, three-dimensional scaffolds, and extraneous signals. Implantation of ‘matured’ constructs is thus expected to provide solution for treating large injury of articular cartilage. Type I collagen is widely used as scaffolds for CTE products undergoing clinical trial, owing to its ubiquitous biocompatibility and vast clinical approval. However, the long-term performance of pure type I collagen scaffolds would suffer from its limited chondrogenic capacity and inferior mechanical properties. This paper aims to provide insights necessary for advancing type I collagen scaffolds in the CTE applications.


We all know that Polynovo is working on using it's scaffold for Cartilage repair!
It will have better properties than those that are collagen based IMHO.

Collagen-Based Biomaterials for Tissue Engineering Applications - PMC

Collagen is the most widely distributed class of proteins in the human body. The use of collagen-based biomaterials in the field of tissue engineering applications has been intensively growing over the past decades. Multiple cross-linking methods ...

www.ncbi.nlm.nih.gov

Abstract​

Collagen is the most widely distributed class of proteins in the human body. The use of collagen-based biomaterials in the field of tissue engineering applications has been intensively growing over the past decades. Multiple cross-linking methods were investigated and different combinations with other biopolymers were explored in order to improve tissue function. Collagen possesses a major advantage in being biodegradable, biocompatible, easily available and highly versatile. However, since collagen is a protein, it remains difficult to sterilize without alterations to its structure. This review presents a comprehensive overview of the various applications of collagen-based biomaterials developed for tissue engineering, aimed at providing a functional material for use in regenerative medicine from the laboratory bench to the patient bedside.

Perhaps they need a better matrix like BTM? which we all know is fully synthetic and does not have the problems associated with collagen based scaffolds!

http://www.neurosurgeryresident.net/TrS.%20Spinal%20trauma/TrS5.%20Spinal%20Trauma.pdf

[/URL]
Page 5

SPINAL TRAUMA TrS5 (5)
Key subacute event is DEMYELINATION (post-traumatic degeneration of white matter) – due to:
1) oligodendrocyte loss (death and limited renewal)
2) ↓ myelin gene expression.
EXPERIMENTAL THERAPIES
NEUROPROTECTIVE AGENTS
1. RILUZOLE – targets excitotoxicity. see p. Spin21 >>
2. BA-210 (Cethrin®) - Rho antagonist; promotes neuroregeneration and neuroprotection.
3. MINOCYCLINE – anti-inflammatory drug.
4. ANTI-NOGO; Nogo-A is myelin-associated neurite outgrowth inhibitory protein limiting recovery
and plasticity after CNS injury.
5. VEGF – stimulates angiogenesis and limits apoptosis.
CELL-BASED THERAPIES
- primarily target myelin repair by restoration of oligodendrocyte population.
Spontaneous remyelination is limited!
 other mechanisms - neuroprotection, trophic factor release, immunomodulation, axon
regeneration
A. Endogenous precursor cells within adult spinal cord - do not promote remyelination (even after
infusion of exogenous growth factors)
B. Cell replacement therapy - potential cell types:
b) embryonic stem cells (ESCs) – ethical issues!!!
N.B. pluripotential stem cells should not be used – potentially oncogenic under trophic
factor stimulation.
c) adult brain-derived NEURAL PRECURSOR CELLS (NPCs) or neural stem cells (NSC)* –
extensive capacity for self-renewal and multipotency in vitro!
 NPCs reside in forebrain (subventricular zone) and spinal cord for life.
 NPCs can be isolated in vitro in the presence of growth factors → formation of clonally
derived free-floating colonies (NEUROSPHERES).
 NSC human transplantation has been reported to improve electromyography and
electrophysiology.
d) mononuclear progenitor cell (MNC)* - either the bone marrow or blood or umbilical cord; reports
of consistent improvements in ASIA grade.
e) Schwann cells (SC)* - from autologous sural nerve
f) olfactory ensheathing cells (OEC)* - from autologous olfactory mucosa
g) mesenchymal stem cells (MSC)* - from bone marrow, umbilical cord, adipose tissue
h) skin-derived precursor cells
i) oligodendrocyte precursor cell (OPC)*
*cells used in published (up to Sept 2020) human trials
Ectopic growth remains a major concern - finite space within the spinal canal and the potential for cord
compression (may take up to 8 yr to manifest).
Rehabilitation after transplantation may be essential for efficacy!
Cell delivery:
a) intramedullary - injection directly into the spinal cord lesion epicenter (e.g. using biomaterial
matrices, notably NeuroRegen Scaffold™ and RMx Biomatrix™)
b) intrathecally – can be done repeatedly.
c) intravenous administration

 

[Lattelarry]

This is interesting at the old place:

Yes the rate of growth has slowed and I think stockrock has a good point but looking forward at what both Macquarie and BoA are predicting, which seems quite likely to me, the current prices seem very good value if you have the patience. 2 years isn't long and I would say once sales are approaching $100M then the SP will be more than double todays. I'm quite comfortable with something if I think it will double in 2 years - thats more than enough growth for me.

Not financial advice and all that.

 

[Moosey]

This is interesting at the old place:
View attachment 1052
Yes the rate of growth has slowed and I think stockrock has a good point but looking forward at what both Macquarie and BoA are predicting, which seems quite likely to me, the current prices seem very good value if you have the patience. 2 years isn't long and I would say once sales are approaching $100M then the SP will be more than double todays. I'm quite comfortable with something if I think it will double in 2 years - thats more than enough growth for me.

View attachment 1053

Not financial advice and all that.

What I do find hard on this site is attracting enough attention, even when there is a great story to tell others, but it's hard when every post just about is on BRN, not that I don't like them but what is posted about any other share gets buried very quickly, what I would suggest is that posters place shares they are interested on a watch list, that way they will get to ses any discussion about that particular share on their watch list.
Or perhaps even place a particular poster on a watch list if you find what they say interesting?

 

[Lattelarry]

Yeah I'm also surprised that more haven't moved over from HC given that its so full of TMH employees posting. I pretty much just look at my watchlist but I guess this means I would easily miss discussion on anything outside this that could potentially be interesting.

 

[kalinda]

It's a slow migration, I don't think there is enough awareness of this awesome alternate option. I keep replying to myself on the LTR thread...

 

[Moosey]

It's a slow migration, I don't think there is enough awareness of this awesome alternate option. I keep replying to myself on the LTR thread...

Yeah I know what you mean.
As an aside, I always thought that Silex would be worth more than Polynovo one day, that is the case now, but not the way I saw it happening, PNV is getting shorted big time and there is no rhyme or reason to it, except for the fact that they may also see PNV being worth a good deal more in the future, I won't be selling mine, looks like BRN may be suffering the same thing and for the same reason and they do this by walking a SP down with ALGO trading! it is pure BS that the average punter has no access to.

 

[Lattelarry]

Yeah I know what you mean.
As an aside, I always thought that Silex would be worth more than Polynovo one day, that is the case now, but not the way I saw it happening, PNV is getting shorted big time and there is no rhyme or reason to it, except for the fact that they may also see PNV being worth a good deal more in the future, I won't be selling mine, looks like BRN may be suffering the same thing and for the same reason and they do this by walking a SP down with ALGO trading! it is pure BS that the average punter has no access to.

I think the algo angle is a bit overdone. Yes its ever present - being able to hide your trades behind it but at the end of the day its supply and demand and if you are a multi-billion dollar fund and you decide to push a small stock one way or another you are going to be able to do it.

I think there's probably another 2 years of this to go until revenue is in the 100M range and hopefully not lumpy by then.
Also the lack of news helps too as most don't have patience. There was a bunch of stuff in the last report that they were meant to update on that we haven't heard about. Hopefully they will update that in the next one in a couple of weeks.

 

[Lattelarry]

New sales manager role posted

 

[Lattelarry]

Also hiring in Florida too

 

[Moosey]

New sales manager role posted
View attachment 1614

Thanks Lattelarry

 

[Lattelarry]

Kickit2me on HC said he posted some charts on another site. He didn't post them here. Does anyone know where he did? I'd like to get them over here too.

 

[Moosey]

Kickit2me on HC said he posted some charts on another site. He didn't post them here. Does anyone know where he did? I'd like to get them over here too.

This was the site where Kickit2me posted https://www.bullseye.net.au/threads
But you have to sign in and become a member!